{"id":1993,"date":"2026-07-25T15:21:28","date_gmt":"2026-07-25T07:21:28","guid":{"rendered":"https:\/\/www.lechengmedical.com\/?p=1993"},"modified":"2026-07-25T15:23:18","modified_gmt":"2026-07-25T07:23:18","slug":"angioexpert-debut-in-china-non-invasive-heart-risk-test-at-lecheng","status":"publish","type":"post","link":"https:\/\/www.lechengmedical.com\/zh\/angioexpert-debut-in-china-non-invasive-heart-risk-test-at-lecheng\/","title":{"rendered":"AngioExpert\u5728\u4e2d\u56fd\u9996\u6b21\u4eae\u76f8\uff1a\u4e50\u57ce\u533b\u9662\u63a8\u51fa\u65e0\u521b\u5fc3\u810f\u98ce\u9669\u68c0\u6d4b"},"content":{"rendered":"

First mainland China application of the skin fluorescence vascular circulation detector marks a new era in non-invasive cardiovascular risk assessment.<\/h2><\/div>
<\/div>
\n

On July 24, 2026, a quiet but profound shift took place in the Boao Lecheng International Medical Tourism Pilot Zone. The AngioExpert<\/strong> \u2013 a skin fluorescence vascular circulation detector developed by Poland-based Angionica \u2013 completed its first clinical application in mainland China at the Boao Yiling Life Care Center. This was not merely the debut of another piece of imported medical equipment. It was the arrival of a technology that promises to change how we think about cardiovascular disease \u2013 moving us from reactive treatment to true early prevention.<\/p>\n<\/div><\/div><\/div>

The Silent Epidemic and the Microcirculation Blind Spot<\/h2><\/div>
<\/div>
\n

Cardiovascular disease has long been the leading cause of death in China, with prevalence continuing to rise and increasingly affecting younger populations. Yet our traditional diagnostic tools have a fundamental limitation: they focus primarily on the structure and function of large blood vessels. By the time these tests yield definitive signals, the disease process is often already well advanced.<\/p>\n

But what if we could detect dysfunction much earlier \u2013 before symptoms appear, before large-vessel damage becomes irreversible? This is where the concept of microcirculation<\/strong> enters the picture. Microcirculation is the terminal network where blood and tissue cells exchange oxygen, nutrients, and waste products. Its dysfunction is an early harbinger of hypertension, diabetes, and atherosclerosis, often appearing years before large-vessel pathology becomes detectable. The challenge has always been how to assess microvascular status non-invasively, sensitively, and reproducibly. AngioExpert was designed to solve exactly that problem.<\/p>\n<\/div><\/div><\/div>

How AngioExpert Works: The Science of Fluorescence<\/h2><\/div>
<\/div>
\n

The AngioExpert employs a technology called flow-mediated skin fluorescence (FMSF)<\/strong>. Here is the principle in plain language: the device measures the fluorescence signal of NADH \u2013 a key coenzyme in cellular metabolism \u2013 within skin tissue cells. When microvascular circulation is impaired, the oxygen supply to skin cells changes, and this is reflected in the NADH fluorescence signal. By analyzing these signals, the device can non-invasively diagnose and monitor microcirculatory disorders, metabolic regulation, and diabetes-related vascular complications.<\/p>\n

What makes this technology truly remarkable is its simplicity. No skin puncture is required<\/strong>. There is no injection, no topical chemical agent. The patient simply places a sensor gently against the forearm skin. The entire test takes about fifteen minutes. It can be repeated as often as needed, and the results are not significantly affected by individual differences in skin pigmentation or thickness. For patients who dread needles or have difficulty with traditional blood draws, this represents a genuine breakthrough in patient comfort and accessibility.<\/p>\n

The device has already received MDR certification from the European Union and has been in use at multiple European clinical institutions. In 2025, it was approved for sale in Taiwan, China, as a Class E (cardiovascular medical science) device. Now, thanks to Lecheng\u2019s \u201cpioneering pilot\u201d policy, it has reached the mainland.<\/p>\n<\/div><\/div><\/div>

The First Patient: A 56-Year-Old\u2019s Journey<\/h2><\/div>
<\/div>
\n

The first patient to experience AngioExpert in mainland China was Mr. Liu, a 56-year-old man. He had been diagnosed with stage 2 hypertension a decade ago and was managing it with oral medication. His previous examinations had revealed elevated lipoprotein(a) and carotid artery plaque formation. He also reported occasional chest tightness.<\/p>\n

\"AngioExpert\u2019s<\/p>\n

Mr. Liu\u2019s case is emblematic of a vast population: individuals with known cardiovascular risk factors who are not yet in crisis, but who walk a fine line between stability and progression. The medical team at Boao Yiling Life Care Center, led by Chief Physician Sun Yong, assessed his condition and recommended that he first undergo microvascular assessment using AngioExpert before determining his\u540e\u7eed treatment plan. The test was performed smoothly, and Mr. Liu became the first person in mainland China to have his microvascular health evaluated through this innovative technology.<\/p>\n

\u201cThis is not just about one patient,\u201d Dr. Sun reflected after the procedure. \u201cIt is about establishing a new standard of care \u2013 one that looks beneath the surface, literally, to catch disease before it catches us.\u201d<\/p>\n<\/div><\/div><\/div>

Why Lecheng? The Power of \u201cPioneering Pilot\u201d<\/h2><\/div>
<\/div>
\n

The AngioExpert\u2019s arrival in China was made possible by Lecheng\u2019s unique \u201cpioneering pilot\u201d policy, which allows innovative medical devices already approved by major international regulators to be introduced and used clinically in the pilot zone before receiving full national approval. This policy has transformed Lecheng into a living laboratory for cutting-edge medicine.<\/p>\n

Since its establishment, the Lecheng Pilot Zone has introduced over 600\u7279\u8bb8 pharmaceuticals, medical devices, and specialty foods<\/strong>, benefiting more than 290,000 patients<\/strong>. The zone\u2019s growing\u96c6\u805a\u6548\u5e94 reflects a broader vision: to achieve \u201cthree synchronizations\u201d \u2013 aligning China\u2019s medical technology, equipment, and pharmaceuticals with international advanced standards. The AngioExpert\u2019s successful debut is a vivid demonstration of that vision in action.<\/p>\n

As Hainan\u2019s Free Trade Port continues to mature, Lecheng\u2019s role as a gateway for global medical innovation is only set to expand. The future, as I see it, is one where patients no longer have to wait years for life-saving or life-enhancing technologies to cross borders.<\/p>\n<\/div><\/div><\/div>

A Call to Action: Know Your Microvascular Health<\/h2><\/div>
<\/div>
\n

As someone who works at the intersection of medical tourism and cutting-edge diagnostics, I have seen too many patients discover their cardiovascular disease only when it is too late. AngioExpert changes that equation. It offers a window into the body\u2019s smallest vessels \u2013 the very places where disease often begins.<\/p>\n

If you have risk factors for cardiovascular disease \u2013 hypertension, diabetes, a family history of heart disease, or simply a concern about your vascular health \u2013 I encourage you to consider this new option. The test is painless, quick, and requires no recovery time. It can be performed as part of a routine health check-up or as a more detailed assessment for those with existing conditions.<\/p>\n

To learn more about AngioExpert or to schedule a consultation at Boao Yiling Life Care Center, please reach out to our international patient services team. We are here to help you take the first step toward a clearer understanding of your heart\u2019s future.<\/p>\n<\/div><\/div><\/div>

<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

\u5728\u535a\u9ccc\u4e50\u57ce\u4f53\u9a8c AngioExpert \u7684\u4e2d\u56fd\u9996\u79c0\u2014\u2014\u8fd9\u662f\u4e00\u6b3e\u65e0\u75db\u3001\u65e0\u9488\u7684\u5fc3\u8840\u7ba1\u98ce\u9669\u8bc4\u4f30\u5de5\u5177\uff0c\u80fd\u591f\u63ed\u793a\u9690\u85cf\u7684\u5fae\u8840\u7ba1\u95ee\u9898\uff0c\u5b9e\u73b0\u65e9\u671f\u9884\u9632\u3002.<\/p>","protected":false},"author":3,"featured_media":1994,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[2,5],"tags":[380,383,381,382],"class_list":["post-1993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breakthroughs","category-therapy","tag-angioexpert","tag-cardiovascular-risk-screening","tag-microcirculation-assessment","tag-non-invasive-cardiovascular-test"],"_links":{"self":[{"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/posts\/1993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/comments?post=1993"}],"version-history":[{"count":1,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/posts\/1993\/revisions"}],"predecessor-version":[{"id":1996,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/posts\/1993\/revisions\/1996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/media\/1994"}],"wp:attachment":[{"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/media?parent=1993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/categories?post=1993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lechengmedical.com\/zh\/wp-json\/wp\/v2\/tags?post=1993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}